Today: 30 June 2026
Browse Category

NYSE:NMR 2 December 2025 - 23 May 2026

Gold Price Near $4,830 Faces Monday Test After Hormuz Reversal Revives Safe-Haven Risk

Gold Watch: $4,500 Level in Focus for Next Move

Gold held close to $4,500 an ounce heading into the weekend, logging a second week of losses. Oil-fueled inflation concerns and rising Federal Reserve rate-hike bets offset some safe-haven demand for bullion. StoneX’s Rhona O’Connell said investors are “fixed upon Hormuz,” tying risks around the Strait of Hormuz to supply chain fears, inflation and chances for higher rates. Spot trading was shut on Saturday. Kitco’s New York spot screen put gold at $4,508.50 bid and $4,510.50 ask at 5 p.m. Friday, a 0.74% drop over the session. Silver lost 1.52%, platinum dropped 2.49%, palladium fell 2.98%.
23 May 2026
··
Silver price breaks $110 to a record as dollar slides on intervention talk and Fed focus

Silver price breaks $110 to a record as dollar slides on intervention talk and Fed focus

London, Jan 26, 2026, 11:02 GMT — Regular session Silver prices surged past $110 an ounce on Monday, marking a new record as investors rushed into precious metals, shunning the dollar. Spot silver hit $110.06 and was last up 6.2% at $109.36 by 0841 GMT. The market jitters were fueled by Trump’s fresh tariff threat—a 100% tariff on Canada linked to a possible China trade deal. Heraeus Metals trader Alexander Zumpfe warned the sharp rally could trigger “sharp interim corrections.”
26 January 2026
··
Macquarie Group (ASX:MQG) Stock Outlook for December 2025: Qube Bid, Nomura Deal and 2026 Forecast

Macquarie Group (ASX:MQG) Stock Outlook for December 2025: Qube Bid, Nomura Deal and 2026 Forecast

Sydney – 2 December 2025 Macquarie Group Limited, Australia’s best‑known investment bank and global infrastructure investor, enters December 2025 in the middle of a major strategic reshaping. The stock is trading around A$193–194 per share, down roughly 10–14% for the year and well below its 2025 highs above A$240, leaving it mid‑range in a 52‑week band of about A$160 to A$243.Intelligent Investor+1
2 December 2025
······

Stock Market Today

  • Theravance Biopharma (TBPH) Slides 3% After $929M Zymeworks (ZYME) Deal Announced
    June 30, 2026, 10:24 AM EDT. Theravance Biopharma (TBPH) shares slipped about 3% on June 29, 2026, after Zymeworks (ZYME) said it would buy the company in an all-cash deal valued at around $929 million. The deal is set to close in H2 2026. Theravance went up for sale after its main drug, ampreloxetine, missed in Phase III trials. Most of Theravance's revenue came from a single COPD collaboration. The buyout gives shareholders $17 per share, which is a 22% premium to the March 3 close, plus CVRs linked to future ampreloxetine proceeds. Management called the move the best route for shareholder value as operational cuts and slow growth continue. Theravance has a Zacks Rank #4 (Sell).
Go toTop